Professor Irene Ng Oi-lin (left) remarks that their next step is to validate relevant biomarkers in larger patient cohorts and to collaborate with clinicians to design clinical trials that combine Resmetirom with immunotherapy and targeted therapy, ultima (IMAGE)

The University of Hong Kong

Professor Irene Ng Oi-lin (left) remarks that their next step is to validate relevant biomarkers in larger patient cohorts and to collaborate with clinicians to design clinical trials that combine Resmetirom with immunotherapy and targeted therapy, ultima

Caption

Professor Irene Ng Oi-lin (left) remarks that their next step is to validate relevant biomarkers in larger patient cohorts and to collaborate with clinicians to design clinical trials that combine Resmetirom with immunotherapy and targeted therapy, ultimately establishing a prevention-oriented treatment approach for high-risk patients.

Credit

HKU

Usage Restrictions

Media

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.